Exton, P. A., (July 1, 2013) - Frontage Laboratories announces two senior appointments to lead its clinical services efforts.
George Laskaris has been named Senior Director, Frontage Biometrics Services, bringing more than 20 years of programming, statistical and data management experience within pharmaceutical and contract research organizations. In this new role, he will spearhead operational management, infrastructure development and growth strategies for Frontage’s clinical programming, statistics and data management groups.
Mr. Laskaris joins Frontage from PRA International, where he managed a team of statistical programmers. Earlier, he worked at several global pharmaceutical companies, serving in a variety of management roles in key clinical research positions.
Alma Villasin, RN, BSN, MBA, joins Frontage as Director, Clinical Operations. She will be responsible for day-to-day oversight of clinical operations and staff training for all study activities, and for oversight of the company’s clinical operations expansion initiative.
Most recently, Ms. Villasin served as Clinical Operations Director for Duke Clinical Research Unit (DCRU), where she oversaw the feasibility and conduct of Phase I-III clinical trials. Prior to DCRU, Ms. Villasin worked at Thomas Jefferson University as Manager of the clinical trials groups. There, she lead a research collaboration on global cardiovascular Phase II/III trials and developed an investigator network in key therapeutic areas such as cardiovascular, endocrinology and family medicine.
"I am delighted to welcome these two talented leaders to Frontage. I am confident they will enable Frontage to continually enhance our service offerings and offer valuable insights to our clients that help solve difficult development challenges , or optimize a clinical development pathway, " said Song Li, Chairman and CEO of Frontage Laboratories. "Our company foundation and success is built upon the efforts and commitment of our internal teams, "he added.
The addition of these two key positions is part of Frontage’s strategy to expand its full-service early phase clinical services, which includes capabilities to conduct a broad range of clinical study types, as well as broadening protocol development, analysis methodology and reporting services supporting later phase trials and programs.
Earlier this year, Frontage’s China Clinical Research Center in Zhengzhou, Henan Province received notable distinction as the recipient of the first successful inspection of a clinical research unit in China, under the FDA’s Human Subject Protection (HSP)/Bioresearch Monitoring (BIMO) Initiative. Launched in 2006 as a part of the Critical Path Initiative, the HSP/BIMO is aimed at modernizing and strengthening the agency’s oversight and protection of subjects in clinical trials and the integrity of resulting data. The inspection results reinforce Frontage’s efforts to build globally accepted quality standards in clinical research.
About Frontage
Frontage Laboratories helps biopharmaceutical organizations advance early-phase research and development with full service offering– including bioanalysis, preclinical and clinical studies, analytical testing and product development support– that spans discovery stages through Phase II clinical trials. Frontage also provides turnkey product development, bioequivalence and analytical services to generic pharmaceutical companies to support ANDA submissions.
With a 12-year history of bioanalytical, clinical research and CMC operations, five state-of-the art research facilities and more than 300 professionals in the US and China, Frontage has enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development and commercial launch in global markets. For more information, visit www.frontagelab.com.